We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hyperapo B and Coronary Heart Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00005168
First Posted: May 26, 2000
Last Update Posted: February 18, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
  Purpose
To determine the role of apolipoprotein B and apolipoprotein A1 in the etiology of coronary artery disease.

Condition
Cardiovascular Diseases Coronary Disease Heart Diseases Diabetes Mellitus Obesity Hypercholesterolemia, Familial

Study Type: Observational

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: August 1984
Study Completion Date: December 1991
Detailed Description:

BACKGROUND:

Hyperapo B is a phenotype defined as elevated plasma level of the major apoprotein B of low density lipoproteins in the presence of a normal plasma level of low density lipoprotein cholesterol. It has been demonstrated that hyperapo B is strongly associated with coronary artery disease. In 1984 when the study began, the independence of this association with other risk factors for coronary artery disease such as cigarette smoking, hypertension, and low plasma levels of high density lipoproteins was not known. The study improved knowledge of the pathophysiology of coronary artery disease and of the genetic and biochemical defects of hyperapo B and hypoalphalipoproteinemia.

DESIGN NARRATIVE:

Interviews were conducted and clinical data collected on each index case and spouse, as well as on first degree relatives. Risk factor data included blood pressure, blood lipid levels, obesity, cigarette smoking, fasting blood sugar and diabetes, hormone use and menopause for women, physical activity, personality scores, and family history. Clinical data included the indications for coronary arteriography, history of use of lipid-lowering agents and insulin, presence of corneal arcus, xanthomata, and xanthelasma, and the electrocardiogram.

To determine if the apolipoprotein B gene and the apolipoprotein A1-C3-A4 gene cluster were independent predictors of premature coronary disease, the relation between DNA polymeric sites within the two genes and coronary disease were investigated using cloned DNA fragments as molecular probes. To determine if apolipoprotein B and apolipoprotein A levels aggregated in families and to determine if hyperapo B and hypoalphalipoproteinemia segregated as Mendelian traits, genetic analysis was conducted in the 200 index cases and the 900 first degree relatives. Studies were also conducted on the linkages between hyperapo B and haplotypes of the apolipoprotein B gene, on hyperapo B and the Ag polymorphisms, and on hyperalphalipoproteinemia and haplotypes of the apolipoprotein A1-C3-A4 gene cluster.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 100 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
No eligibility criteria
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Publications:
Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO Jr. Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis. 1984 Mar-Apr;4(2):79-83. Review.
Sniderman A, Teng B, Genest J, Cianflone K, Wacholder S, Kwiterovich P Jr. Familial aggregation and early expression of hyperapobetalipoproteinemia. Am J Cardiol. 1985 Feb 1;55(4):291-5.
Teng B, Sniderman A, Krauss RM, Kwiterovich PO Jr, Milne RW, Marcel YL. Modulation of apolipoprotein B antigenic determinants in human low density lipoprotein subclasses. J Biol Chem. 1985 Apr 25;260(8):5067-72.
Kwiterovich PO Jr, Bachorik PS, Franklin FA Jr, Margolis S, Georgopoulos L, Teng B, Sniderman AD. Effect of dietary treatment on the plasma levels of lipids, lipoprotein cholesterol and LDL B protein in children with type II hyperlipoproteinemia. Prog Clin Biol Res. 1985;188:123-37.
Beaty TH, Kwiterovich PO Jr, Khoury MJ, White S, Bachorik PS, Smith HH, Teng B, Sniderman A. Genetic analysis of plasma sitosterol, apoprotein B, and lipoproteins in a large Amish pedigree with sitosterolemia. Am J Hum Genet. 1986 Apr;38(4):492-504.
Genest J, Sniderman A, Cianflone K, Teng B, Wacholder S, Marcel Y, Kwiterovich P Jr. Hyperapobetalipoproteinemia. Plasma lipoprotein responses to oral fat load. Arteriosclerosis. 1986 May-Jun;6(3):297-304.
Kwiterovich P, Beaty T, Bachorik P, Chen J, Franklin F, Georgopoulos L, Sniderman A. Pediatric hyperlipoproteinemia: the phenotypic expression of hyperapobetalipoproteinemia in young probands and their parents. Prog Clin Biol Res. 1988;255:89-105.
Kwiterovich PO Jr, White S, Forte T, Bachorik PS, Smith H, Sniderman A. Hyperapobetalipoproteinemia in a kindred with familial combined hyperlipidemia and familial hypercholesterolemia. Arteriosclerosis. 1987 May-Jun;7(3):211-25.
Sniderman A, Kwiterovich PO Jr: Hyperapobetalipoproteinemia and LDL and HDL2 Heterogenity. Proceedings of the Workshop on Lipoprotein Heterogeneity, U.S. Department of Health and Human Services, NIH Publication No. 87-2646, pp 293-304, 1987
Beaty TH, Kwiterovich PO, Laville A, Lewis B. Genetic analysis of total cholesterol and triglycerides in a pedigree of St. Thomas rabbits. J Lipid Res. 1989 Mar;30(3):387-94.
Ma YH, Ladias JA, Bütler R, Schumaker VN, Antonarakis SE, Lusis AJ, Heinzman C, Kwiterovich PO. Apolipoprotein B gene haplotypes. Association between Ag and DNA polymorphisms. Arteriosclerosis. 1988 Sep-Oct;8(5):521-4.
Kwiterovich PO Jr. Biochemical, clinical, genetic and metabolic studies of hyperapo-beta-lipoproteinaemia. J Inherit Metab Dis. 1988;11 Suppl 1:57-73. Review.
Kwiterovich PO Jr. HyperapoB: a pleiotropic phenotype characterized by dense low-density lipoproteins and associated with coronary artery disease. Clin Chem. 1988;34(8B):B71-7. Review.
Bachorik PS, Kwiterovich PO Jr. Apolipoprotein measurements in clinical biochemistry and their utility vis-a-vis conventional assays. Clin Chim Acta. 1988 Nov;178(1):1-34. Review.
Ladias JA, Kwiterovich PO Jr, Smith HH, Miller M, Bachorik PS, Forte T, Lusis AJ, Antonarakis SE. Apolipoprotein B-100 Hopkins (arginine4019----tryptophan). A new apolipoprotein B-100 variant in a family with premature atherosclerosis and hyperapobetalipoproteinemia. JAMA. 1989 Oct 13;262(14):1980-8.
Kwiterovich PO. Genetic influences on susceptibility to atherosclerosis in the young. Bull N Y Acad Med. 1989 Dec;65(10):1092-108; discussion 1154-60. Review.
Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO Jr, Pearson TA. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol. 1990 Nov;16(6):862-70.
Ladias JA, Kwiterovich PO Jr, Smith HH, Karathanasis SK, Antonarakis SE. Apolipoprotein A1 Baltimore (Arg10----Leu), a new ApoA1 variant. Hum Genet. 1990 Apr;84(5):439-45.
Beaty TH, Prenger VL, Virgil DG, Lewis B, Kwiterovich PO, Bachorik PS. A genetic model for control of hypertriglyceridemia and apolipoprotein B levels in the Johns Hopkins colony of St. Thomas Hospital rabbits. Genetics. 1992 Dec;132(4):1095-104.
Prenger VL, Beaty TH, Kwiterovich PO. Genetic determination of high-density lipoprotein-cholesterol and apolipoprotein A-1 plasma levels in a family study of cardiac catheterization patients. Am J Hum Genet. 1992 Nov;51(5):1047-57.
Coresh J, Beaty TH, Kwiterovich PO Jr, Antonarakis SE. Pedigree and sib-pair linkage analysis suggest the apolipoprotein B gene is not the major gene influencing plasma apolipoprotein B levels. Am J Hum Genet. 1992 May;50(5):1038-45.
Kwiterovich PO Jr, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol. 1992 Apr 15;69(12):1015-21.
Heizmann C, Kirchgessner T, Kwiterovich PO, Ladias JA, Derby C, Antonarakis SE, Lusis AJ. DNA polymorphism haplotypes of the human lipoprotein lipase gene: possible association with high density lipoprotein levels. Hum Genet. 1991 Apr;86(6):578-84.
Miller M, Bell W, Plano S, Connors J, Kennedy S, Kwiterovich P. Platelet aggregation in hyperapobetalipoproteinemia. Am J Hematol. 1991 Jul;37(3):209-11.
Kwiterovich PO Jr, Motevalli M, Miller M, Bachorik PS, Kafonek SD, Chatterjee S, Beaty T, Virgil D. Further insights into the pathophysiology of hyperapobetalipoproteinemia: role of basic proteins I, II, III. Clin Chem. 1991 Mar;37(3):317-26. Review.
Kwiterovich P Jr, Motevalli M, Miller M. Acylation-stimulatory activity in hyperapobetalipoproteinemic fibroblasts: enhanced cholesterol esterification with another serum basic protein, BP II. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8980-4.
Miller M, Kwiterovich PO Jr. Isolated low HDL-cholesterol as an important risk factor for coronary heart disease. Eur Heart J. 1990 Dec;11 Suppl H:9-14. Review.

ClinicalTrials.gov Identifier: NCT00005168     History of Changes
Other Study ID Numbers: 1042
R01HL031497 ( U.S. NIH Grant/Contract )
First Submitted: May 25, 2000
First Posted: May 26, 2000
Last Update Posted: February 18, 2016
Last Verified: May 2000

Additional relevant MeSH terms:
Diabetes Mellitus
Cardiovascular Diseases
Heart Diseases
Hypercholesterolemia
Coronary Disease
Coronary Artery Disease
Hyperlipoproteinemia Type II
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Myocardial Ischemia
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hyperlipoproteinemias


To Top